Long-term anticholinergic use and the aging brain

Xueya Cai, Noll Campbell, Babar Khan, Christopher Callahan, Malaz Boustani

Research output: Contribution to journalArticle

66 Citations (Scopus)

Abstract

Background: Older Americans are facing an epidemic of chronic diseases and are thus exposed to anticholinergics (ACs) that might negatively affect their risk of developing mild cognitive impairment (MCI) or dementia. Objective: To investigate the association between impairment in cognitive function and previous AC exposure. Design: A retrospective cohort study. Setting: Primary care clinics in Indianapolis, Indiana. Participants: A total of 3690 older adults who have undergone cognitive assessment and had a 1-year medication-dispensing record. Outcome: Cognitive function was measured in two sequential steps: a two-step screening process followed by a formal diagnostic process for participants with positive screening results. Exposure: Three patterns of AC exposure were defined by the duration of AC exposure, the number of AC medications dispensed at the same time, and the severity of AC effects as determined by the Anticholinergic Cognitive Burden list. Results: Compared with older adults with no AC exposure and after adjusting for age, race, gender, and underlying comorbidity, the odds ratio for having a diagnosis of MCI was 2.73 (95% confidence interval, 1.27-5.87) among older adults who were exposed to at least three possible ACs for at least 90 days; the odds ratio for having dementia was 0.43 (95% confidence interval, 0.10-1.81). Conclusion: Exposure to medications with severe AC cognitive burden may be a risk factor for developing MCI.

Original languageEnglish
Pages (from-to)377-385
Number of pages9
JournalAlzheimer's and Dementia
Volume9
Issue number4
DOIs
StatePublished - Jul 2013

Fingerprint

Cholinergic Antagonists
Brain
Cognition
Dementia
Odds Ratio
Confidence Intervals
Comorbidity
Primary Health Care
Chronic Disease
Cohort Studies
Retrospective Studies

Keywords

  • Anticholinergics
  • Cognitive impairment
  • Dementia
  • Elderly
  • Mild cognitive impairment

ASJC Scopus subject areas

  • Health Policy
  • Epidemiology
  • Geriatrics and Gerontology
  • Psychiatry and Mental health
  • Cellular and Molecular Neuroscience
  • Developmental Neuroscience
  • Clinical Neurology

Cite this

Long-term anticholinergic use and the aging brain. / Cai, Xueya; Campbell, Noll; Khan, Babar; Callahan, Christopher; Boustani, Malaz.

In: Alzheimer's and Dementia, Vol. 9, No. 4, 07.2013, p. 377-385.

Research output: Contribution to journalArticle

@article{d58d26cc70124c1eb47a61b823b3ec72,
title = "Long-term anticholinergic use and the aging brain",
abstract = "Background: Older Americans are facing an epidemic of chronic diseases and are thus exposed to anticholinergics (ACs) that might negatively affect their risk of developing mild cognitive impairment (MCI) or dementia. Objective: To investigate the association between impairment in cognitive function and previous AC exposure. Design: A retrospective cohort study. Setting: Primary care clinics in Indianapolis, Indiana. Participants: A total of 3690 older adults who have undergone cognitive assessment and had a 1-year medication-dispensing record. Outcome: Cognitive function was measured in two sequential steps: a two-step screening process followed by a formal diagnostic process for participants with positive screening results. Exposure: Three patterns of AC exposure were defined by the duration of AC exposure, the number of AC medications dispensed at the same time, and the severity of AC effects as determined by the Anticholinergic Cognitive Burden list. Results: Compared with older adults with no AC exposure and after adjusting for age, race, gender, and underlying comorbidity, the odds ratio for having a diagnosis of MCI was 2.73 (95{\%} confidence interval, 1.27-5.87) among older adults who were exposed to at least three possible ACs for at least 90 days; the odds ratio for having dementia was 0.43 (95{\%} confidence interval, 0.10-1.81). Conclusion: Exposure to medications with severe AC cognitive burden may be a risk factor for developing MCI.",
keywords = "Anticholinergics, Cognitive impairment, Dementia, Elderly, Mild cognitive impairment",
author = "Xueya Cai and Noll Campbell and Babar Khan and Christopher Callahan and Malaz Boustani",
year = "2013",
month = "7",
doi = "10.1016/j.jalz.2012.02.005",
language = "English",
volume = "9",
pages = "377--385",
journal = "Alzheimer's and Dementia",
issn = "1552-5260",
publisher = "Elsevier Inc.",
number = "4",

}

TY - JOUR

T1 - Long-term anticholinergic use and the aging brain

AU - Cai, Xueya

AU - Campbell, Noll

AU - Khan, Babar

AU - Callahan, Christopher

AU - Boustani, Malaz

PY - 2013/7

Y1 - 2013/7

N2 - Background: Older Americans are facing an epidemic of chronic diseases and are thus exposed to anticholinergics (ACs) that might negatively affect their risk of developing mild cognitive impairment (MCI) or dementia. Objective: To investigate the association between impairment in cognitive function and previous AC exposure. Design: A retrospective cohort study. Setting: Primary care clinics in Indianapolis, Indiana. Participants: A total of 3690 older adults who have undergone cognitive assessment and had a 1-year medication-dispensing record. Outcome: Cognitive function was measured in two sequential steps: a two-step screening process followed by a formal diagnostic process for participants with positive screening results. Exposure: Three patterns of AC exposure were defined by the duration of AC exposure, the number of AC medications dispensed at the same time, and the severity of AC effects as determined by the Anticholinergic Cognitive Burden list. Results: Compared with older adults with no AC exposure and after adjusting for age, race, gender, and underlying comorbidity, the odds ratio for having a diagnosis of MCI was 2.73 (95% confidence interval, 1.27-5.87) among older adults who were exposed to at least three possible ACs for at least 90 days; the odds ratio for having dementia was 0.43 (95% confidence interval, 0.10-1.81). Conclusion: Exposure to medications with severe AC cognitive burden may be a risk factor for developing MCI.

AB - Background: Older Americans are facing an epidemic of chronic diseases and are thus exposed to anticholinergics (ACs) that might negatively affect their risk of developing mild cognitive impairment (MCI) or dementia. Objective: To investigate the association between impairment in cognitive function and previous AC exposure. Design: A retrospective cohort study. Setting: Primary care clinics in Indianapolis, Indiana. Participants: A total of 3690 older adults who have undergone cognitive assessment and had a 1-year medication-dispensing record. Outcome: Cognitive function was measured in two sequential steps: a two-step screening process followed by a formal diagnostic process for participants with positive screening results. Exposure: Three patterns of AC exposure were defined by the duration of AC exposure, the number of AC medications dispensed at the same time, and the severity of AC effects as determined by the Anticholinergic Cognitive Burden list. Results: Compared with older adults with no AC exposure and after adjusting for age, race, gender, and underlying comorbidity, the odds ratio for having a diagnosis of MCI was 2.73 (95% confidence interval, 1.27-5.87) among older adults who were exposed to at least three possible ACs for at least 90 days; the odds ratio for having dementia was 0.43 (95% confidence interval, 0.10-1.81). Conclusion: Exposure to medications with severe AC cognitive burden may be a risk factor for developing MCI.

KW - Anticholinergics

KW - Cognitive impairment

KW - Dementia

KW - Elderly

KW - Mild cognitive impairment

UR - http://www.scopus.com/inward/record.url?scp=84882449192&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84882449192&partnerID=8YFLogxK

U2 - 10.1016/j.jalz.2012.02.005

DO - 10.1016/j.jalz.2012.02.005

M3 - Article

C2 - 23183138

AN - SCOPUS:84882449192

VL - 9

SP - 377

EP - 385

JO - Alzheimer's and Dementia

JF - Alzheimer's and Dementia

SN - 1552-5260

IS - 4

ER -